-+ 0.00%
-+ 0.00%
-+ 0.00%

Lucid Diagnostics Q2 FY26 revenue rises 25% to USD 1.5 million

PUBT·08/12/2026 20:32:28
Listen to the news
Lucid Diagnostics Q2 FY26 revenue rises 25% to USD 1.5 million
  • Lucid Diagnostics posted Q2 revenue of USD 1.5 million, up 25% from a year earlier.
  • Sales and marketing expense climbed to USD 5.8 million from USD 4 million on higher compensation and personnel-related costs.
  • General and administrative expense edged up to USD 5.8 million from USD 5.6 million, reflecting higher compensation partly offset by lower financing-related fees.
  • Cash on hand totaled USD 33.4 million at June 30, 2026; the company used USD 23.4 million of cash in operations in H1.
  • Business updates included a VA contract award, a first positive lab benefit manager coverage policy in July 2026, and USD 16.8 million net proceeds from an April equity offering.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-027335), on August 12, 2026, and is solely responsible for the information contained therein.